TILRAY COLLABORATES ON BRAIN-CANCER CLINICAL TRIAL SLATED TO START NEXT MONTH

STUDY LOOKS AT SAFETY OF SHRINKING BRAIN-CANCER TUMOURS USING MIXTURE OF THC, CBD AND CHEMO-THERAPY

Tilray is collaborating with The Spanish Group for Neuro-oncology in an open-label clinical trial involving 30 patients with newly diagnosed glioblastoma, an aggressive form of brain cancer.

+Slated to start in July 2019, according to clinical-trial records updated on May 31, 2019.

+Primary completion expected by June 2020.

+Builds on previous research that showed a clear anti-tumour effect when THC, CBD, TMZ and radiotherapy were combined in pre-clinical glioma models.

+Cannabinoids have been shown to destroy tumour cells by “activating” receptors in the brain and in the immune system, in experimental research.

+1:1 ratio of THC and CBD will be involved in the open-label clinical trial.

The Spanish Group for Neuro-oncology (Grupo Español de Investigación en Neurooncologíais) is sponsoring the research.

Collaborators include the Medical Cannabis Bike Tour, Voices Against Brain Cancer and Tilray. 

 

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s